Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results

Share :
Published: 15 Jun 2018
Views: 3093
Rating:
Save
Dr Olivier Casasnovas - CHU de Dijon, Dijon, France

Dr Casanovas speaks with ecancer at EHA 23 about disease control with BEACOPP in patients with advanced Hodgkin lymphoma.

He discusses the trial design, receiving either 6 cycles of BEACOPP or ABVD chemotherapy depending on PET imaging results, and the consistency in responses between the two trial arms.

The tolerability of BEACOPP treatment-based treatment and higher PFS and OS recommend it as a standard of care.

For more on these results, watch his presentation of the results at a press session.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.